Longer Course of Imatinib Better in Trial for GI Stromal Tumor

This article originally appeared here.
Longer Course of Imatinib Better in Trial for GI Stromal Tumor
Longer Course of Imatinib Better in Trial for GI Stromal Tumor

(HealthDay News) – A longer course of imatinib (36 months vs. 12 months) significantly improves recurrence-free survival (RFS) and overall survival in postoperative patients at high risk for recurrence of gastrointestinal stromal tumor (GIST), according to a study published in the March 28 issue of the Journal of the American Medical Association.

Heikki Joensuu, MD, of Helsinki University, and colleagues conducted a randomized, open-label phase 3 study in 24 hospitals in Finland, Germany, Norway, and Sweden. Patients were given imatinib (400mg per day) orally for either 12 or 36 months; treatment was initiated within 12 weeks of surgery. The risk of GIST recurrence was estimated using the modified National Institutes of Health Consensus Criteria.

Over the median follow-up of 54 months, the researchers found that patients assigned to 36 months of imatinib had significantly longer RFS compared with those assigned to 12 months (hazard ratio [HR], 0.46; five-year RFS, 65.6% vs. 47.9%) and longer overall survival (HR, 0.45; five-year survival, 92% vs. 81.7%). Imatinib was generally well tolerated, but 12.6% of patients assigned to the 12-month group and 25.8% of patients assigned to the 36-month group discontinued imatinib for a reason other than GIST recurrence.

"Compared with 12 months of adjuvant imatinib, 36 months of imatinib improved RFS and overall survival of GIST patients with a high risk of GIST recurrence," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which partially funded the study.

Abstract
Full Text
Editorial (subscription or payment may be required)